Compare Novartis AG (NVS) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Novartis AG trades at $139.98 (market cap $262.64B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.05. The key difference: Novartis AG pays a 3.44% dividend while Vanguard Tax Managed Fund FTSE Developed Markets ETF pays none, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VEA | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | — |
52-Week High | $168.62 | $73.79 |
52-Week Low | $121.80 | $58.90 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
Vanguard FTSE Developed Markets ETF (VEA) trades at $73.46, down 0.41% on the day but near its 52-week high of $74.04. Technical indicators show a bullish trend with strong moving average support, while oscillators are neutral. Recent news highlights increased institutional buying, such as Allianz Asset Management boosting its stake by 11.8% in Q2 2026 (Defense World, 2026-09-09). The ETF offers low-cost exposure to developed international markets, with an expense ratio of 0.03% (The Motley Fool, 2026-08-20).
VEA's outlook is supported by institutional accumulation and cost efficiency, but risks include concentration in developed markets missing emerging growth. Proximity to the 52-week high suggests limited near-term upside without broader international market momentum. Investors benefit from diversification outside the U.S., though currency fluctuations and geopolitical events pose headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
